Literature DB >> 7544805

Regulation of arachidonic acid, eicosanoid, and phospholipase A2 levels in murine mast cells by recombinant stem cell factor.

A N Fonteh1, J M Samet, F H Chilton.   

Abstract

The current study evaluates the capacity of recombinant rat stem cell factor (rrSCF) to regulate enzymes that control AA release and eicosanoid generation in mouse bone marrow-derived mast cells (BMMCs). Initial studies indicated that rrSCF provided for 24 h inhibited the release of AA into supernatant fluids of antigen- and ionophore A23187-stimulated BMMCs. Agonist-induced increases in cellular levels of AA were also inhibited, albeit to a lesser degree by rrSCF. To determine the inhibitory mechanism, several steps (e.g., mobilization of cytosolic calcium, release of BMMC granules, and regulation of phospholipase A2 [PLA2] activity) that could influence AA release were measured in rrSCF-treated cells. rrSCF did not alter the capacity of BMMCs to mobilize cytosolic calcium or release histamine in response to antigen and ionophore. BMMCs released large amounts of PLA2 with characteristics of the group II family in response to antigen and ionophore A23187. rrSCF treatment of BMMCs reduced the secretion of this PLA2 activity by BMMCs. Partial purification of acid-extractable PLA2 from rrSCF-treated and untreated BMMCs suggested that rrSCF decreased the quantity of acid-stable PLA2 within the cells. In contrast to group II PLA2, the quantity of cPLA2 (as determined by Western blot analysis) increased in response to rrSCF. To assess the ramifications of rrSCF-induced reductions in AA and group II PLA2, eicosanoid formation was measured in antigen- and ionophore-stimulated BMMCs, rrSCF-inhibited (100 ng/ml, 24 h) prostaglandin D2 (PGD2), thromboxane B2, and leukotriene B4 by 48.4 +/- 7.7%, 61.1 +/- 10.0% AND 38.1 +/- 3.6%, respectively, in antigen-stimulated cells. Similar patterns of inhibition were observed in ionophore-stimulated BMMCs. The addition of a group I PLA2 or exogenous AA to BMMCs reversed the inhibition of eicosanoid generation induced by rrSCF. Together, these data indicate that rrSCF differentially regulates group II and cytosolic PLA2 activities in BMMCs. The resultant reductions in eicosanoid generation suggest that group II PLA2 provides a portion of AA that is used for eicosanoid biosynthesis by BMMCs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544805      PMCID: PMC185766          DOI: 10.1172/JCI118179

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  72 in total

1.  Molecular cloning of pancreatic group I phospholipase A2 receptor.

Authors:  J Ishizaki; K Hanasaki; K Higashino; J Kishino; N Kikuchi; O Ohara; H Arita
Journal:  J Biol Chem       Date:  1994-02-25       Impact factor: 5.157

Review 2.  Diversity of group types, regulation, and function of phospholipase A2.

Authors:  E A Dennis
Journal:  J Biol Chem       Date:  1994-05-06       Impact factor: 5.157

3.  Evidence that secretory phospholipase A2 plays a role in arachidonic acid release and eicosanoid biosynthesis by mast cells.

Authors:  A N Fonteh; D A Bass; L A Marshall; M Seeds; J M Samet; F H Chilton
Journal:  J Immunol       Date:  1994-06-01       Impact factor: 5.422

4.  Enhanced expression of group II phospholipase A2 in human hepatocellular carcinoma.

Authors:  Z Ying; H Tojo; T Komatsubara; M Nakagawa; M Inada; S Kawata; Y Matsuzawa; M Okamoto
Journal:  Biochim Biophys Acta       Date:  1994-05-25

5.  Angiotensin II stimulates phosphorylation of high-molecular-mass cytosolic phospholipase A2 in vascular smooth-muscle cells.

Authors:  G N Rao; B Lassègue; R W Alexander; K K Griendling
Journal:  Biochem J       Date:  1994-04-01       Impact factor: 3.857

6.  Cytoplasmic phospholipase A2 translocates to membrane fraction in human neutrophils activated by stimuli that phosphorylate mitogen-activated protein kinase.

Authors:  M Durstin; S Durstin; T F Molski; E L Becker; R I Sha'afi
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

7.  Bacterial lipopolysaccharide primes human neutrophils for enhanced release of arachidonic acid and causes phosphorylation of an 85-kD cytosolic phospholipase A2.

Authors:  M E Doerfler; J Weiss; J D Clark; P Elsbach
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

8.  Interleukin 1 alpha causes rapid activation of cytosolic phospholipase A2 by phosphorylation in rat mesangial cells.

Authors:  J Gronich; M Konieczkowski; M H Gelb; R A Nemenoff; J R Sedor
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

9.  Interferon-gamma induces the synthesis and activation of cytosolic phospholipase A2.

Authors:  T Wu; S J Levine; M G Lawrence; C Logun; C W Angus; J H Shelhamer
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

10.  Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency.

Authors:  S Yamashita; J Yamashita; M Ogawa
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

View more
  4 in total

1.  Nanoliposomal delivery of cytosolic phospholipase A2 inhibitor arachidonyl trimethyl ketone for melanoma treatment.

Authors:  Raghavendra Gowda; Saketh S Dinavahi; Soumya Iyer; Shubhadeep Banerjee; Rogerio I Neves; Colette R Pameijer; Gavin P Robertson
Journal:  Nanomedicine       Date:  2018-01-06       Impact factor: 5.307

Review 2.  Regulation and metabolism of arachidonic acid.

Authors:  M C Seeds; D A Bass
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

3.  Stress response pathways protect germ cells from omega-6 polyunsaturated fatty acid-mediated toxicity in Caenorhabditis elegans.

Authors:  Christopher M Webster; Marshall L Deline; Jennifer L Watts
Journal:  Dev Biol       Date:  2012-10-09       Impact factor: 3.582

Review 4.  Pathologic thrombopoiesis of rheumatoid arthritis.

Authors:  Ihsan Ertenli; Sedat Kiraz; M Akif Oztürk; Ibrahim c Haznedaroğlu; Ismail Celik; Meral Calgüneri
Journal:  Rheumatol Int       Date:  2003-02-11       Impact factor: 2.631

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.